GlassScriptPhysician profile
Erika S Manis
NPI 1659630770
$3,552.29
in general payments reported to CMS, 2019-2025
19 companies · $330 in 2025
The $330 reported for 2025 was less than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $411 · 2020: $1,072 · 2021: $128 · 2022: $370 · 2023: $756 · 2024: $485 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,282 · Education: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,282.40 |
| Education | $288.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,125.37 | 2019-2025 | Inspire |
| Jazz Pharmaceuticals INC. | $757.52 | 2019-2025 | |
| Harmony Biosciences LLC | $440.32 | 2020-2025 | Wakix |
| Axsome Therapeutics, INC. | $397.34 | 2022-2025 | Sunosi |
| Idorsia Pharmaceuticals US INC | $204.33 | 2023-2024 | Quviviq |
| Philips North America LLC | $123.64 | 2019-2023 | |
| Glaxosmithkline, LLC. | $108.42 | 2019-2021 | |
| Avadel Cns Pharmaceuticals, LLC | $104.33 | 2024-2025 | Lumryz |
| Takeda Pharmaceuticals U.S.A., INC. | $52.30 | 2020-2022 | |
| Baxter Healthcare | $43.74 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.43 | 2020-2024 | Ofev |
| Amgen INC. | $28.17 | 2022 | |
| Fisher & Paykel Healthcare INC | $27.72 | 2020-2024 | Fisher & Paykel Healthcare |
| 3b Medical, INC. | $24.76 | 2023 | Luna |
| Lilly USA, LLC | $15.99 | 2025 | Zepbound |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $15.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $14.95 | 2022 | |
| Astellas Pharma US INC | $13.82 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erika Manis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.